US Drug Discovery Market Size, Share, and Trends 2026 to 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on US Drug Discovery Market 

5.1. COVID-19 Landscape: US Drug Discovery Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. US Drug Discovery Market, By End User

8.1. US Drug Discovery Market, by End User Type

8.1.1. Pharmaceutical Companies

8.1.1.1. Market Revenue and Forecast

8.1.2. CROs

8.1.2.1. Market Revenue and Forecast

8.1.3. Others

8.1.3.1. Market Revenue and Forecast

Chapter 9. US Drug Discovery Market, By Drug Type

9.1. US Drug Discovery Market, by Drug Type

9.1.1. Small Molecule

9.1.1.1. Market Revenue and Forecast

9.1.2. Large Molecule

9.1.2.1. Market Revenue and Forecast

Chapter 10. US Drug Discovery Market, Regional Estimates and Trend Forecast

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by End User

11.1.4.2. Market Revenue and Forecast, by Drug Type

Chapter 11. Company Profiles

12.1. Pfizer Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. GlaxoSmithKline PLC

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Merck & Co. Inc.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Agilent Technologies Inc.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Eli Lilly and Company

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. F. Hoffmann-La Roche Ltd

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Bayer AG

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Abbott Laboratories Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. AstraZeneca PLC

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Shimadzu Corp

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 12. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 13. Appendix

14.1. About Us

14.2. Glossary of Terms